Location History:
- Yunnan, CN (2019)
- Kunming, CN (2020)
Company Filing History:
Years Active: 2019-2025
Title: Longyan Zhao: Innovator in Antithrombotic Research
Introduction
Longyan Zhao is a prominent inventor based in Kunming, China. He has made significant contributions to the field of pharmaceuticals, particularly in the development of antithrombotic agents. With a total of 3 patents, Zhao's work focuses on innovative compounds that can inhibit coagulation factors, which are crucial in preventing thrombotic diseases.
Latest Patents
Zhao's latest patents include groundbreaking research on oligosaccharide compounds. One of his notable inventions is an oligosaccharide compound for inhibiting the intrinsic coagulation factor X-enzyme complex. This invention includes a purified oligosaccharide compound with antithrombotic activity, a preparation method for the mixture, and its uses in drug development for preventing and treating thrombotic diseases. Another significant patent is for a Fuc3S4S substituted oligoglycosaminoglycan, which has a weight-average molecular weight of about 4.5-9 kD. This compound also has applications in preparing medicines aimed at preventing and treating thrombotic conditions.
Career Highlights
Throughout his career, Longyan Zhao has worked with notable companies in the pharmaceutical industry, including Jiuzhitang Co., Ltd. and Mudanjiang Youbo Pharmaceutical Co., Ltd. His experience in these organizations has allowed him to advance his research and contribute to the development of effective therapeutic solutions.
Collaborations
Zhao has collaborated with several professionals in his field, including Jinhua Zhao and Na Gao. These partnerships have facilitated the exchange of ideas and expertise, further enhancing the impact of his work.
Conclusion
Longyan Zhao's innovative research in antithrombotic compounds positions him as a key figure in the pharmaceutical industry. His patents reflect a commitment to advancing medical science and improving treatment options for thrombotic diseases.